Cost-Effectiveness Analysis of the High-Dose Trivalent Influenza Vaccine in the Elderly Population in Italy
The findings suggest that the high-dose vaccine may improve health outcomes while reducing healthcare costs in people aged 65 and over in Italy.
High-Dose vs Standard-Dose Influenza Vaccines in Older Adults: A Meta-Analysis
Among adults 65 years and older, does high-dose inactivated influenza vaccine (HD-IIV) provide superior protection against hospitalization and mortality compared with the standard dose?
Influenza Vaccine and Associated Infection and Death in California, 2024 to 2025
Among adults aged 65 years and older with laboratory confirmed influenza, vaccination was associated with 29% lower likelihood of death due to influenza-related causes.
Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Updated analysis incorporating new evidence
HD-IIV remains cost-effective in Dutch adults aged ≥60.
Comparative Effectiveness of High-Dose and Standard-Dose Influenza Vaccines for Hospitalisation and Mortality in Adults Aged 65 and Older: An Updated Systematic Review and Meta-Analysis
High-dose inactivated influenza vaccine (HD-IV) provides superior protection compared with SD-IV against P&I and all-cause hospitalisation in older adults, with the greatest benefits among younger seniors and those without cardiovascular disease.
Adjuvanted vs High-Dose Influenza Vaccines in Older US Adults
A Cluster Randomized Crossover Study
Summary Report: IDC Stakeholder Community Meeting - 10 June 2026, Brussels
Key takeaways and next steps from the first in-person meeting of the IDC
Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients
In two open-label trials, nirmatrelvir–ritonavir did not reduce the incidence of hospitalization or death among vaccinated higher-risk participants with SARS-CoV-2 infection.